ESTRO 2025 - Abstract Book

S916

Clinical - Haematology

ESTRO 2025

References: Yegya-Raman N, Wright C, LaRiviere M, Baron J, Lee D, Landsburg D, et al. Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clinical and Translational Radiation Oncology (2023). https://doi.org/10.1016/j.ctro.2023.100587 Bramanti S, Mannina D, Chiappella A. et al. Role of bridging RT in relapsed/ refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409 024-02427-8

4260

Proffered Paper Role of radiotherapy in advance-stage Hodgkin lymphoma with bulky disease: a systematic review and meta-analysis Ahmed Salem 1,2 , Ahmad Masoud 3 , Mohammad Alsheikh 3 , Jenan Alfayyoumi 3 , Ftoon Abu bader 3 , Zaid Daboubi 3 , Abdelmomen Hassan 3 , Salah Ibrahim 3 , Rama Alkhatib 3 , Ranya Alsallal 3 , Lujen Alelaimat 3 , Louai Alsaloumi 4 , Fanar Al Samarat 3 1 Department of Anatomy, Physiology and Biochemistry, The Hashemite University, zarqa, Jordan. 2 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. 3 Faculty of Medicine, Hashemite University, Zarqa, Jordan. 4 Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Isra University, Amman, Jordan Purpose/Objective: Hodgkin lymphoma (HL) is a relatively uncommon neoplasm primarily affecting young adults. The primary treatment for HL is chemotherapy, sometimes combined with radiotherapy for early-stage disease. The role of consolidation radiotherapy in advanced HL, particularly for patients with bulky disease is unknown. The objective of this meta-analysis is to consolidate existing evidence and assess the effectiveness of radiotherapy in patients with advanced-stage HL and bulky disease who achieve complete remission after chemotherapy. Material/Methods: We included studies that compared the benefit of adding radiotherapy versus no additional treatment to the bulky site in advanced HL (stages IIB-IV) after achieving complete remission (CR) to chemotherapy. The primary endpoint was progression-free survival (PFS). Data were expressed as odds ratio (OR) with 95% confidence intervals (CI). The analysis was performed in RevMan 5.3 software (Cochrane Collaboration, Oxford, UK). The level of significance was defined as α=0.05. Publication bias was evaluated through trim and fill analysis. This meta-analysis was designed according to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and was registered in the Prospero database (CRD42024593942). Results: A total of 1,219 patients from seven studies published between 1994-2022 were included (568 patients received no radiotherapy and 651 patients received radiotherapy); Figure 1 . The median age for no radiotherapy and radiotherapy groups was 31 and 31.75 years, respectively. The median follow-up duration was 71 months (range: 40-91 months). The chemotherapy regimens used across the studies were: ABVD (N=3, 33.33%), MOPP/ABVD (N=2, 22.22%), and ABVD/BEACOPP, BEACOPP, MOP-BAP, VEBEP (each N=1, 11.11%). The number of cycles administered ranged from 2-8 cycles. The median dose of radiotherapy was 30Gy (range: 30-32Gy). Patients who received radiotherapy had 1.81 times higher odds of remaining progression-free compared to those in the control group (OR=1.81, 95% CI=1.12–2.94, p=0.02); Figure 2 . A borderline significant heterogeneity among the studies was found (p=0.06). However, the consistency of results across different datasets reinforces the reliability of the meta-analytic conclusions regarding effect sizes and their uncertainty.